LEVERKUSEN (Dow Jones) – The outgoing chief executive of Bayer AG, Werner Wenning , estimates the total market for anticoagulant such as one’s own resources " Xarelto "to 12 billion to 15 billion USD annually. Here are the key chronic indications , the manager told reporters on Tuesday evening . ( Reuters photo 🙂
Xarelto is currently approved in more than 100 countries, only in thrombosis prophylaxis in adult patients, and hip or knee replacement surgery. "A small business "as Wenning said.
Would Xarelto authorized in all possible indications , Bayer expects peak annual sales of 2 billion EUR. Xarelto was for Bayer " a very important asset , "explained Wenning. Barclays Capital had recently the market for blood thinners to 2021 estimated at 12 billion USD annually . In numerous other indications the drug is currently being investigated.
The pharmaceutical companies currently provide a competition in the market for anticoagulants . In addition , Bayer will have this , Boehringer Ingelheim, decide on their funds ‘ Pradaxa "the U.S. Food and Drug Administration in mid-September , and Bristol- Myers Squibb and Pfizer, the positive data in late August for their product " Apixaban submitted .
– By Natali Schwab , Dow Jones Newswires, +49 69 29725119 ,
natali.schwab @ dowjones.com
DJG / nas / jhe / sh